Xinhua Zhao, PhD

Articles

March 15th 2018

Trends in Opioid and Nonsteroidal Anti-Inflammatory Use and Adverse Events

Veronica Fassio, PharmD Sherrie L. Aspinall, PharmD, MSc Xinhua Zhao, PhD Donald R. Miller, ScD Jasvinder A. Singh, MD, MPH Chester B. Good, MD, MPH Francesca E. Cunningham, PharmD

Opioid use incidence and prevalence rates decreased with implementation of an opioid safety initiative, whereas nonsteroidal anti-inflammatory drug rates remained constant. Rates of adverse events were higher among opioid users.

September 19th 2013

FDA Warning and Removal of Rosiglitazone From VA National Formulary

Sherrie L. Aspinall, PharmD, MSc Xinhua Zhao, PhD Chester B. Good, MD, MPH Roslyn A. Stone, PhD Kenneth J. Smith, MD, MS Francesca E. Cunningham, PharmD

After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.